Strain Name:

CBy.129S1-Il12rb2tm1Jm/J

Stock Number:

003642

Order this mouse

Availability:

Cryopreserved - Ready for recovery

Use Restrictions Apply, see Terms of Use

Description

The genotypes of the animals provided may not reflect those discussed in the strain description or the mating scheme utilized by The Jackson Laboratory prior to cryopreservation. Please inquire for possible genotypes for this specific strain.

Strain Information

Type Congenic; Mutant Strain; Targeted Mutation;
Additional information on Genetically Engineered and Mutant Mice.
Visit our online Nomenclature tutorial.
Additional information on Congenic nomenclature.
Specieslaboratory mouse
Background Strain BALB/cByJ
Donor Strain 129S1 via W9.5 ES (+Kitl-SlJ) ES cell line
 
Donating Investigator The Jackson Laboratory,  

Description
Mice homozygous for the Il12rb2tm1Jm targeted mutation are viable and fertile. Homozygous mutant mice do not show an increased susceptibility to infections. In an attempt to offer alleles on well-characterized or multiple genetic backgrounds, alleles are frequently moved to a genetic background different from that on which an allele was first characterized. This is the case for the strain above. It should be noted that the phenotype could vary from that originally described. We will modify the strain description if necessary as published results become available.

Control Information

  Control
   See control note: BALB/cByJ mice (Stock No. 001026) may be used as controls.
   001026 BALB/cByJ
 
  Considerations for Choosing Controls

Related Strains

Strains carrying   Il12rb2tm1Jm allele
003248   B6.129S1-Il12rb2tm1Jm/J
View Strains carrying   Il12rb2tm1Jm     (1 strain)

Strains carrying other alleles of Il12rb2
022303   B6N(Cg)-Il12rb2tm1.1(KOMP)Vlcg/J
View Strains carrying other alleles of Il12rb2     (1 strain)

Phenotype

Phenotype Information

View Mammalian Phenotype Terms

Mammalian Phenotype Terms provided by MGI
      assigned by genotype

The following phenotype information is associated with a similar, but not exact match to this JAX® Mice strain.

Il12rb2tm1Jm/Il12rb2tm1Jm

        either: (involves: 129S1/Sv * BALB/cByJ) or (involves: 129S1/Sv * C57BL/6J)
  • immune system phenotype
  • abnormal lymphocyte physiology
    • absence of IL12-stimulated IFNG production or proliferation in Con A-activated splenocytes; however, when stimulated with IL2 proliferation of splenocytes is similar to wild-type   (MGI Ref ID J:65891)
    • lymph node cells from keyhole limpet hemocyanin (KLH) immunized mice fail to produce IFNG when cultured with KLH   (MGI Ref ID J:65891)
    • secretion of IFNG in response to either anti-CD3 antibody or Con A stimulation is severely impaired   (MGI Ref ID J:65891)
    • abnormal NK cell physiology
      • natural killer lytic activity of splenocytes is enhanced in response to IL2 but not IL12   (MGI Ref ID J:65891)
  • hematopoietic system phenotype
  • abnormal lymphocyte physiology
    • absence of IL12-stimulated IFNG production or proliferation in Con A-activated splenocytes; however, when stimulated with IL2 proliferation of splenocytes is similar to wild-type   (MGI Ref ID J:65891)
    • lymph node cells from keyhole limpet hemocyanin (KLH) immunized mice fail to produce IFNG when cultured with KLH   (MGI Ref ID J:65891)
    • secretion of IFNG in response to either anti-CD3 antibody or Con A stimulation is severely impaired   (MGI Ref ID J:65891)
    • abnormal NK cell physiology
      • natural killer lytic activity of splenocytes is enhanced in response to IL2 but not IL12   (MGI Ref ID J:65891)

Il12rb2tm1Jm/Il12rb2tm1Jm

        B6.129S1-Il12rb2tm1Jm/J
  • homeostasis/metabolism phenotype
  • increased circulating interleukin-12 level   (MGI Ref ID J:120061)
  • immune system phenotype
  • abnormal B cell activation
    • B cells express high levels of the early activation marker CD69   (MGI Ref ID J:106805)
  • abnormal T cell activation
    • T cells express high levels of the early activation marker CD69   (MGI Ref ID J:106805)
  • glomerulonephritis
    • mesangio-proliferative glomerulonephritis in 21 of 26 mice that first manifests at the age of 3 months and progresses with age   (MGI Ref ID J:106805)
  • increased anti-nuclear antigen antibody level
    • development of secondary lymphoid follicles and CD138+plasma-cell hyperplasia is observed in the spleen and lymph nodes   (MGI Ref ID J:106805)
  • increased circulating interleukin-12 level   (MGI Ref ID J:120061)
  • increased interleukin-6 secretion
    • in spleen of 13 to 26 month old mice   (MGI Ref ID J:106805)
  • liver inflammation
    • diffuse lymphocyte bundles   (MGI Ref ID J:106805)
  • lymphoid hyperplasia
    • CD138+ plasma-cell hyperplasia is observed in the spleen and lymph nodes   (MGI Ref ID J:106805)
  • salivary gland inflammation
    • diffuse lymphocyte bundles   (MGI Ref ID J:106805)
    • submandibular gland inflammation
      • diffuse lymphocyte bundles   (MGI Ref ID J:106805)
  • tumorigenesis
  • abnormal tumor vascularization
    • microvessel density is significantly reduced in B16 melanoma derived tumors   (MGI Ref ID J:120061)
  • altered tumor morphology
    • characterized by a wide focus of ischemic-coagulative necrosis 17 days after B16 injection   (MGI Ref ID J:120061)
    • tumor cells have a significantly lower proliferation index and higher number of apoptotic cells 17 days after B16 injection than wild-type mice   (MGI Ref ID J:120061)
    • decreased tumor growth/size
      • decreased B16 melonama derived tumor size 17 days after subcutaneous injection   (MGI Ref ID J:120061)
  • increased lung carcinoma incidence
    • epithelial lung tumors such as bronchoalveolar carcinoma of the lung in older mice   (MGI Ref ID J:106805)
  • increased plasmacytoma incidence
    • 4 of 13 mice older than 12 months show mature plasmacytoma histologic features   (MGI Ref ID J:106805)
  • cardiovascular system phenotype
  • abnormal tumor vascularization
    • microvessel density is significantly reduced in B16 melanoma derived tumors   (MGI Ref ID J:120061)
  • renal/urinary system phenotype
  • glomerulonephritis
    • mesangio-proliferative glomerulonephritis in 21 of 26 mice that first manifests at the age of 3 months and progresses with age   (MGI Ref ID J:106805)
  • hematopoietic system phenotype
  • abnormal B cell activation
    • B cells express high levels of the early activation marker CD69   (MGI Ref ID J:106805)
  • abnormal T cell activation
    • T cells express high levels of the early activation marker CD69   (MGI Ref ID J:106805)
  • liver/biliary system phenotype
  • liver inflammation
    • diffuse lymphocyte bundles   (MGI Ref ID J:106805)
  • digestive/alimentary phenotype
  • abnormal parotid gland morphology
  • salivary gland inflammation
    • diffuse lymphocyte bundles   (MGI Ref ID J:106805)
    • submandibular gland inflammation
      • diffuse lymphocyte bundles   (MGI Ref ID J:106805)
  • endocrine/exocrine gland phenotype
  • abnormal parotid gland morphology
  • salivary gland inflammation
    • diffuse lymphocyte bundles   (MGI Ref ID J:106805)
    • submandibular gland inflammation
      • diffuse lymphocyte bundles   (MGI Ref ID J:106805)
View Research Applications

Research Applications
This mouse can be used to support research in many areas including:

Il12rb2tm1Jm related

Cancer Research
Growth Factors/Receptors/Cytokines

Immunology, Inflammation and Autoimmunity Research
Growth Factors/Receptors/Cytokines

Genes & Alleles

Gene & Allele Information provided by MGI

 
Allele Symbol Il12rb2tm1Jm
Allele Name targeted mutation 1, Jeanne Magram
Allele Type Targeted (Null/Knockout)
Common Name(s) IL-12Rbeta2-; IL-12Rbeta2KO;
Mutation Made ByDr. David Presky,   Hoffman-La Roche, Inc.
Strain of Origin129S1/Sv-Oca2<+> Tyr<+> Kitl<+>
ES Cell Line NameW9.5/W95
ES Cell Line Strain129S1/Sv-Oca2<+> Tyr<+> Kitl<+>
Gene Symbol and Name Il12rb2, interleukin 12 receptor, beta 2
Chromosome 6
Gene Common Name(s) A930027I18Rik; IL-12RB2; Ifnm; RIKEN cDNA A930027I18 gene; interferon response to microorganisms;
Molecular Note A neomycin resistance cassette replaced exons 2 and 3 of the gene, deleting the ATG translation initiation codon, the signal peptide, and the N-terminal immunoglobulin domain of the receptor. [MGI Ref ID J:65891]

Genotyping

Genotyping Information

Genotyping Protocols

Il12rb2tm1Jm, Melt Curve Analysis
Il12rb2tm1Jm, Standard PCR


Helpful Links

Genotyping resources and troubleshooting

References

References provided by MGI

Selected Reference(s)

Wu Cy; Wang X; Gadina M; O'Shea JJ; Presky DH; Magram J. 2000. IL-12 receptor ss2 (IL-12Rss2)-deficient mice are defective in IL-12-mediated signaling despite the presence of high affinity IL-12 binding sites J Immunol 165(11):6221-8. [PubMed: 11086056]  [MGI Ref ID J:65891]

Additional References

Il12rb2tm1Jm related

Airoldi I; Di Carlo E; Cocco C; Sorrentino C; Fais F; Cilli M; D'Antuono T; Colombo MP; Pistoia V. 2005. Lack of Il12rb2 signaling predisposes to spontaneous autoimmunity and malignancy. Blood 106(12):3846-53. [PubMed: 16081683]  [MGI Ref ID J:106805]

Airoldi I; Di Carlo E; Cocco C; Taverniti G; D'Antuono T; Ognio E; Watanabe M; Ribatti D; Pistoia V. 2007. Endogenous IL-12 triggers an antiangiogenic program in melanoma cells. Proc Natl Acad Sci U S A 104(10):3996-4001. [PubMed: 17360466]  [MGI Ref ID J:120061]

Brahmachari S; Pahan K. 2009. Suppression of regulatory T cells by IL-12p40 homodimer via nitric oxide. J Immunol 183(3):2045-58. [PubMed: 19587012]  [MGI Ref ID J:151706]

Brown GR; Lee EL; El-Hayek J; Kintner K; Luck C. 2005. IL-12-independent LIGHT signaling enhances MHC class II disparate CD4+ T cell alloproliferation, IFN-gamma responses, and intestinal graft-versus-host disease. J Immunol 174(8):4688-95. [PubMed: 15814693]  [MGI Ref ID J:109999]

Cao X; Leonard K; Collins LI; Cai SF; Mayer JC; Payton JE; Walter MJ; Piwnica-Worms D; Schreiber RD; Ley TJ. 2009. Interleukin 12 stimulates IFN-gamma-mediated inhibition of tumor-induced regulatory T-cell proliferation and enhances tumor clearance. Cancer Res 69(22):8700-9. [PubMed: 19843867]  [MGI Ref ID J:154453]

Chakir H; Campos-Neto A; Mojibian M; Webb JR. 2003. IL-12Rbeta2-deficient mice of a genetically resistant background are susceptible to Leishmania major infection and develop a parasite-specific Th2 immune response. Microbes Infect 5(4):241-9. [PubMed: 12706437]  [MGI Ref ID J:105826]

Chakir H; Lemay AM; Webb JR. 2001. Cytokine expression by murine DX5+ cells in response to IL-12, IL-18, or the combination of IL-12 and IL-18. Cell Immunol 212(1):71-81. [PubMed: 11716531]  [MGI Ref ID J:114011]

Codarri L; Gyulveszi G; Tosevski V; Hesske L; Fontana A; Magnenat L; Suter T; Becher B. 2011. RORgammat drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation. Nat Immunol 12(6):560-7. [PubMed: 21516112]  [MGI Ref ID J:172802]

Coers J; Vance RE; Fontana MF; Dietrich WF. 2007. Restriction of Legionella pneumophila growth in macrophages requires the concerted action of cytokine and Naip5/Ipaf signalling pathways. Cell Microbiol 9(10):2344-57. [PubMed: 17506816]  [MGI Ref ID J:148669]

Collison LW; Delgoffe GM; Guy CS; Vignali KM; Chaturvedi V; Fairweather D; Satoskar AR; Garcia KC; Hunter CA; Drake CG; Murray PJ; Vignali DA. 2012. The composition and signaling of the IL-35 receptor are unconventional. Nat Immunol 13(3):290-9. [PubMed: 22306691]  [MGI Ref ID J:181328]

Cui W; Joshi NS; Liu Y; Meng H; Kleinstein SH; Kaech SM. 2014. TLR4 ligands lipopolysaccharide and monophosphoryl lipid a differentially regulate effector and memory CD8+ T Cell differentiation. J Immunol 192(9):4221-32. [PubMed: 24659688]  [MGI Ref ID J:209988]

Eisenring M; vom Berg J; Kristiansen G; Saller E; Becher B. 2010. IL-12 initiates tumor rejection via lymphoid tissue-inducer cells bearing the natural cytotoxicity receptor NKp46. Nat Immunol 11(11):1030-8. [PubMed: 20935648]  [MGI Ref ID J:166535]

Evel-Kabler K; Song XT; Aldrich M; Huang XF; Chen SY. 2006. SOCS1 restricts dendritic cells' ability to break self tolerance and induce antitumor immunity by regulating IL-12 production and signaling. J Clin Invest 116(1):90-100. [PubMed: 16357940]  [MGI Ref ID J:105256]

Fauconnier M; Palomo J; Bourigault ML; Meme S; Szeremeta F; Beloeil JC; Danneels A; Charron S; Rihet P; Ryffel B; Quesniaux VF. 2012. IL-12Rbeta2 is essential for the development of experimental cerebral malaria. J Immunol 188(4):1905-14. [PubMed: 22238458]  [MGI Ref ID J:181195]

Galbiati F; Rogge L; Adorini L. 2000. IL-12 receptor regulation in IL-12-deficient BALB/c and C57BL/6 mice. Eur J Immunol 30(1):29-37. [PubMed: 10602024]  [MGI Ref ID J:59230]

Ghiringhelli F; Apetoh L; Tesniere A; Aymeric L; Ma Y; Ortiz C; Vermaelen K; Panaretakis T; Mignot G; Ullrich E; Perfettini JL; Schlemmer F; Tasdemir E; Uhl M; Genin P; Civas A; Ryffel B; Kanellopoulos J; Tschopp J; Andre F; Lidereau R; McLaughlin NM; Haynes NM; Smyth MJ; Kroemer G; Zitvogel L. 2009. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med 15(10):1170-8. [PubMed: 19767732]  [MGI Ref ID J:154302]

Gyulveszi G; Haak S; Becher B. 2009. IL-23-driven encephalo-tropism and Th17 polarization during CNS-inflammation in vivo. Eur J Immunol 39(7):1864-1869. [PubMed: 19544494]  [MGI Ref ID J:150273]

Henry CJ; Ornelles DA; Mitchell LM; Brzoza-Lewis KL; Hiltbold EM. 2008. IL-12 produced by dendritic cells augments CD8+ T cell activation through the production of the chemokines CCL1 and CCL17. J Immunol 181(12):8576-84. [PubMed: 19050277]  [MGI Ref ID J:142058]

Huang G; Wang Y; Shi LZ; Kanneganti TD; Chi H. 2011. Signaling by the Phosphatase MKP-1 in Dendritic Cells Imprints Distinct Effector and Regulatory T Cell Fates. Immunity 35(1):45-58. [PubMed: 21723158]  [MGI Ref ID J:174378]

Jana M; Dasgupta S; Pal U; Pahan K. 2009. IL-12 p40 homodimer, the so-called biologically inactive molecule, induces nitric oxide synthase in microglia via IL-12R beta 1. Glia 57(14):1553-65. [PubMed: 19306359]  [MGI Ref ID J:156200]

Jana M; Mondal S; Jana A; Pahan K. 2014. Interleukin-12 (IL-12), but not IL-23, induces the expression of IL-7 in microglia and macrophages: implications for multiple sclerosis. Immunology 141(4):549-63. [PubMed: 24224652]  [MGI Ref ID J:211495]

Kastenmuller W; Torabi-Parizi P; Subramanian N; Lammermann T; Germain RN. 2012. A spatially-organized multicellular innate immune response in lymph nodes limits systemic pathogen spread. Cell 150(6):1235-48. [PubMed: 22980983]  [MGI Ref ID J:187962]

Keppler SJ; Aichele P. 2011. Signal 3 requirement for memory CD8+ T-cell activation is determined by the infectious pathogen. Eur J Immunol 41(11):3176-86. [PubMed: 21830209]  [MGI Ref ID J:179523]

Keppler SJ; Theil K; Vucikuja S; Aichele P. 2009. Effector T-cell differentiation during viral and bacterial infections: Role of direct IL-12 signals for cell fate decision of CD8(+) T cells. Eur J Immunol 39(7):1774-1783. [PubMed: 19548244]  [MGI Ref ID J:150269]

Kerkar SP; Goldszmid RS; Muranski P; Chinnasamy D; Yu Z; Reger RN; Leonardi AJ; Morgan RA; Wang E; Marincola FM; Trinchieri G; Rosenberg SA; Restifo NP. 2011. IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. J Clin Invest 121(12):4746-57. [PubMed: 22056381]  [MGI Ref ID J:184027]

Kim DJ; Youn JI; Seo SH; Jin HT; Sung YC. 2008. Differential regulation of antigen-specific CD8+ T cell responses by IL-12p40 in a dose-dependent manner. J Immunol 180(11):7167-74. [PubMed: 18490715]  [MGI Ref ID J:136348]

King IL; Segal BM. 2005. Cutting edge: IL-12 induces CD4+CD25- T cell activation in the presence of T regulatory cells. J Immunol 175(2):641-5. [PubMed: 16002658]  [MGI Ref ID J:100673]

Klezovich-Benard M; Corre JP; Jusforgues-Saklani H; Fiole D; Burjek N; Tournier JN; Goossens PL. 2012. Mechanisms of NK cell-macrophage Bacillus anthracis crosstalk: a balance between stimulation by spores and differential disruption by toxins. PLoS Pathog 8(1):e1002481. [PubMed: 22253596]  [MGI Ref ID J:195407]

Klose CS; Kiss EA; Schwierzeck V; Ebert K; Hoyler T; d'Hargues Y; Goppert N; Croxford AL; Waisman A; Tanriver Y; Diefenbach A. 2013. A T-bet gradient controls the fate and function of CCR6-RORgammat+ innate lymphoid cells. Nature 494(7436):261-5. [PubMed: 23334414]  [MGI Ref ID J:194555]

Knowles H; Heizer JW; Li Y; Chapman K; Ogden CA; Andreasen K; Shapland E; Kucera G; Mogan J; Humann J; Lenz LL; Morrison AD; Perraud AL. 2011. Transient Receptor Potential Melastatin 2 (TRPM2) ion channel is required for innate immunity against Listeria monocytogenes. Proc Natl Acad Sci U S A 108(28):11578-83. [PubMed: 21709234]  [MGI Ref ID J:174397]

Koch MA; Thomas KR; Perdue NR; Smigiel KS; Srivastava S; Campbell DJ. 2012. T-bet(+) Treg Cells Undergo Abortive Th1 Cell Differentiation due to Impaired Expression of IL-12 Receptor beta2. Immunity 37(3):501-10. [PubMed: 22960221]  [MGI Ref ID J:187671]

Kurche JS; Burchill MA; Sanchez PJ; Haluszczak C; Kedl RM. 2010. Comparison of OX40 Ligand and CD70 in the Promotion of CD4+ T Cell Responses. J Immunol 185(4):2106-15. [PubMed: 20639485]  [MGI Ref ID J:162543]

Laffont S; Seillet C; Ortaldo J; Coudert JD; Guery JC. 2008. Natural killer cells recruited into lymph nodes inhibit alloreactive T-cell activation through perforin-mediated killing of donor allogeneic dendritic cells. Blood 112(3):661-71. [PubMed: 18505782]  [MGI Ref ID J:138424]

Langowski JL; Zhang X; Wu L; Mattson JD; Chen T; Smith K; Basham B; McClanahan T; Kastelein RA; Oft M. 2006. IL-23 promotes tumour incidence and growth. Nature 442(7101):461-5. [PubMed: 16688182]  [MGI Ref ID J:111568]

Lee SH; Fragoso MF; Biron CA. 2012. Cutting edge: a novel mechanism bridging innate and adaptive immunity: IL-12 induction of CD25 to form high-affinity IL-2 receptors on NK cells. J Immunol 189(6):2712-6. [PubMed: 22888135]  [MGI Ref ID J:189815]

Matsuda JL; Gapin L; Baron JL; Sidobre S; Stetson DB; Mohrs M; Locksley RM; Kronenberg M. 2003. Mouse V alpha 14i natural killer T cells are resistant to cytokine polarization in vivo. Proc Natl Acad Sci U S A 100(14):8395-400. [PubMed: 12829795]  [MGI Ref ID J:126209]

Melillo AA; Foreman O; Elkins KL. 2013. IL-12Rbeta2 is critical for survival of primary Francisella tularensis LVS infection. J Leukoc Biol 93(5):657-67. [PubMed: 23440500]  [MGI Ref ID J:200796]

Nanjappa SG; Heninger E; Wuthrich M; Gasper DJ; Klein BS. 2012. Tc17 cells mediate vaccine immunity against lethal fungal pneumonia in immune deficient hosts lacking CD4+ T cells. PLoS Pathog 8(7):e1002771. [PubMed: 22829762]  [MGI Ref ID J:195376]

Nishikomori R; Usui T; Wu CY; Morinobu A; O'Shea JJ; Strober W. 2002. Activated STAT4 has an essential role in Th1 differentiation and proliferation that is independent of its role in the maintenance of IL-12Rbeta2 chain expression and signaling. J Immunol 169(8):4388-98. [PubMed: 12370372]  [MGI Ref ID J:79543]

Park Y; Kim HS; Ahn JY; Yun D; Cho ML; Hong S; Kim HY; Chung DH. 2010. IL-12p35 promotes antibody-induced joint inflammation by activating NKT cells and suppressing TGF-beta. J Immunol 185(3):1476-84. [PubMed: 20581146]  [MGI Ref ID J:162473]

Pearce EL; Shen H. 2007. Generation of CD8 T cell memory is regulated by IL-12. J Immunol 179(4):2074-81. [PubMed: 17675465]  [MGI Ref ID J:151232]

Robinson RT; Khader SA; Martino CA; Fountain JJ; Teixeira-Coelho M; Pearl JE; Smiley ST; Winslow GM; Woodland DL; Walter MJ; Conejo-Garcia JR; Gubler U; Cooper AM. 2010. Mycobacterium tuberculosis infection induces il12rb1 splicing to generate a novel IL-12Rbeta1 isoform that enhances DC migration. J Exp Med 207(3):591-605. [PubMed: 20212068]  [MGI Ref ID J:158809]

Russell TD; Yan Q; Fan G; Khalifah AP; Bishop DK; Brody SL; Walter MJ. 2003. IL-12 p40 homodimer-dependent macrophage chemotaxis and respiratory viral inflammation are mediated through IL-12 receptor beta1. J Immunol 171(12):6866-74. [PubMed: 14662893]  [MGI Ref ID J:86929]

Settles EW; Moser LA; Harris TH; Knoll LJ. 2014. Toxoplasma gondii upregulates interleukin-12 to prevent Plasmodium berghei-induced experimental cerebral malaria. Infect Immun 82(3):1343-53. [PubMed: 24396042]  [MGI Ref ID J:209405]

Sorensen EW; Gerber SA; Frelinger JG; Lord EM. 2010. IL-12 suppresses vascular endothelial growth factor receptor 3 expression on tumor vessels by two distinct IFN-gamma-dependent mechanisms. J Immunol 184(4):1858-66. [PubMed: 20061409]  [MGI Ref ID J:159492]

Sun JC; Madera S; Bezman NA; Beilke JN; Kaplan MH; Lanier LL. 2012. Proinflammatory cytokine signaling required for the generation of natural killer cell memory. J Exp Med 209(5):947-54. [PubMed: 22493516]  [MGI Ref ID J:185151]

Vonarbourg C; Mortha A; Bui VL; Hernandez PP; Kiss EA; Hoyler T; Flach M; Bengsch B; Thimme R; Holscher C; Honig M; Pannicke U; Schwarz K; Ware CF; Finke D; Diefenbach A. 2010. Regulated expression of nuclear receptor RORgammat confers distinct functional fates to NK cell receptor-expressing RORgammat(+) innate lymphocytes. Immunity 33(5):736-51. [PubMed: 21093318]  [MGI Ref ID J:167005]

Williams CA; Murray SE; Weinberg AD; Parker DC. 2007. OX40-mediated differentiation to effector function requires IL-2 receptor signaling but not CD28, CD40, IL-12Rbeta2, or T-bet. J Immunol 178(12):7694-702. [PubMed: 17548606]  [MGI Ref ID J:148588]

Wilson DC; Matthews S; Yap GS. 2008. IL-12 Signaling Drives CD8+ T Cell IFN-{gamma} Production and Differentiation of KLRG1+ Effector Subpopulations during Toxoplasma gondii Infection. J Immunol 180(9):5935-45. [PubMed: 18424713]  [MGI Ref ID J:134314]

Wuthrich M; Gern B; Hung CY; Ersland K; Rocco N; Pick-Jacobs J; Galles K; Filutowicz H; Warner T; Evans M; Cole G; Klein B. 2011. Vaccine-induced protection against 3 systemic mycoses endemic to North America requires Th17 cells in mice. J Clin Invest 121(2):554-68. [PubMed: 21206087]  [MGI Ref ID J:171835]

Zhao Z; Yu S; Fitzgerald DC; Elbehi M; Ciric B; Rostami AM; Zhang GX. 2008. IL-12Rbeta2 promotes the development of CD4+CD25+ regulatory T cells. J Immunol 181(6):3870-6. [PubMed: 18768841]  [MGI Ref ID J:139108]

Health & husbandry

Health & Colony Maintenance Information

Animal Health Reports

Production of mice from cryopreserved embryos or sperm occurs in a maximum barrier room, G200.

Pricing and Purchasing

Pricing, Supply Level & Notes, Controls


Pricing for USA, Canada and Mexico shipping destinations View International Pricing

Cryopreserved

Cryopreserved Mice - Ready for Recovery

Price (US dollars $)
Cryorecovery* $2525.00
Animals Provided

At least two mice that carry the mutation (if it is a mutant strain) will be provided. Their genotypes may not reflect those discussed in the strain description. Please inquire for possible genotypes and see additional details below.

Standard Supply

Cryopreserved. Ready for recovery. Please refer to pricing and supply notes on the strain data sheet for further information.

Supply Notes

  • Cryorecovery - Standard.
    Progeny testing is not required.

    The average number of mice provided from recovery of our cryopreserved strains is 10. The total number of animals provided, their gender and genotype will vary. We will fulfill your order by providing at least two pair of mice, at least one animal of each pair carrying the mutation of interest. Please inquire if larger numbers of animals with specific genotype and genders are needed. Animals typically ship between 10 and 14 weeks from the date of your order. If a second cryorecovery is needed in order to provide the minimum number of animals, animals will ship within 25 weeks. IMPORTANT NOTE: The genotypes of animals provided may not reflect the mating scheme utilized by The Jackson Laboratory prior to cryopreservation, or that discussed in the strain description. Please inquire about possible genotypes which will be recovered for this specific strain. The Jackson Laboratory cannot guarantee the reproductive success of mice shipped to your facility. If the mice are lost after the first three days (post-arrival) or do not produce progeny at your facility, a new order and fee will be necessary.

    Cryorecovery to establish a Dedicated Supply for greater quantities of mice. Mice recovered can be used to establish a dedicated colony to contractually supply you mice according to your requirements. Price by quotation. For more information on Dedicated Supply, please contact JAX® Services, Tel: 1-800-422-6423 (from U.S.A., Canada or Puerto Rico only) or 1-207-288-5845 (from any location).

Pricing for International shipping destinations View USA Canada and Mexico Pricing

Cryopreserved

Cryopreserved Mice - Ready for Recovery

Price (US dollars $)
Cryorecovery* $3283.00
Animals Provided

At least two mice that carry the mutation (if it is a mutant strain) will be provided. Their genotypes may not reflect those discussed in the strain description. Please inquire for possible genotypes and see additional details below.

Standard Supply

Cryopreserved. Ready for recovery. Please refer to pricing and supply notes on the strain data sheet for further information.

Supply Notes

  • Cryorecovery - Standard.
    Progeny testing is not required.

    The average number of mice provided from recovery of our cryopreserved strains is 10. The total number of animals provided, their gender and genotype will vary. We will fulfill your order by providing at least two pair of mice, at least one animal of each pair carrying the mutation of interest. Please inquire if larger numbers of animals with specific genotype and genders are needed. Animals typically ship between 10 and 14 weeks from the date of your order. If a second cryorecovery is needed in order to provide the minimum number of animals, animals will ship within 25 weeks. IMPORTANT NOTE: The genotypes of animals provided may not reflect the mating scheme utilized by The Jackson Laboratory prior to cryopreservation, or that discussed in the strain description. Please inquire about possible genotypes which will be recovered for this specific strain. The Jackson Laboratory cannot guarantee the reproductive success of mice shipped to your facility. If the mice are lost after the first three days (post-arrival) or do not produce progeny at your facility, a new order and fee will be necessary.

    Cryorecovery to establish a Dedicated Supply for greater quantities of mice. Mice recovered can be used to establish a dedicated colony to contractually supply you mice according to your requirements. Price by quotation. For more information on Dedicated Supply, please contact JAX® Services, Tel: 1-800-422-6423 (from U.S.A., Canada or Puerto Rico only) or 1-207-288-5845 (from any location).

View USA Canada and Mexico Pricing View International Pricing

Standard Supply

Cryopreserved. Ready for recovery. Please refer to pricing and supply notes on the strain data sheet for further information.

Control Information

  Control
   See control note: BALB/cByJ mice (Stock No. 001026) may be used as controls.
   001026 BALB/cByJ
 
  Considerations for Choosing Controls
  Control Pricing Information for Genetically Engineered Mutant Strains.
 

Payment Terms and Conditions

Terms are granted by individual review and stated on the customer invoice(s) and account statement. These transactions are payable in U.S. currency within the granted terms. Payment for services, products, shipping containers, and shipping costs that are rendered are expected within the payment terms indicated on the invoice or stated by contract. Invoices and account balances in arrears of stated terms may result in The Jackson Laboratory pursuing collection activities including but not limited to outside agencies and court filings.


See Terms of Use tab for General Terms and Conditions


The Jackson Laboratory's Genotype Promise

The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project.
Ordering Information
JAX® Mice
Surgical and Preconditioning Services
JAX® Services
Customer Services and Support
Tel: 1-800-422-6423 or 1-207-288-5845
Fax: 1-207-288-6150
Technical Support Email Form

Terms of Use

Terms of Use


General Terms and Conditions


For Licensing and Use Restrictions view the link(s) below:
- Use of MICE by companies or for-profit entities requires a license prior to shipping.

Contact information

General inquiries regarding Terms of Use

Contracts Administration

phone:207-288-6470

JAX® Mice, Products & Services Conditions of Use

"MICE" means mouse strains, their progeny derived by inbreeding or crossbreeding, unmodified derivatives from mouse strains or their progeny supplied by The Jackson Laboratory ("JACKSON"). "PRODUCTS" means biological materials supplied by JACKSON, and their derivatives. "RECIPIENT" means each recipient of MICE, PRODUCTS, or services provided by JACKSON including each institution, its employees and other researchers under its control. MICE or PRODUCTS shall not be: (i) used for any purpose other than the internal research, (ii) sold or otherwise provided to any third party for any use, or (iii) provided to any agent or other third party to provide breeding or other services. Acceptance of MICE or PRODUCTS from JACKSON shall be deemed as agreement by RECIPIENT to these conditions, and departure from these conditions requires JACKSON's prior written authorization.

No Warranty

MICE, PRODUCTS AND SERVICES ARE PROVIDED “AS IS”. JACKSON EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.

In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of mice, products or services, JACKSON will, at its option, provide credit or replacement for the mice or product received or the services provided.

No Liability

In no event shall JACKSON, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, PRODUCTS or services, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of JACKSON, its agents or employees. Unless prohibited by law, in purchasing or receiving MICE, PRODUCTS or services from JACKSON, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges JACKSON from all such causes of action or damages, and further agrees to defend and indemnify JACKSON from any costs or damages arising out of any third party claims.

MICE and PRODUCTS are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.

The foregoing represents the General Terms and Conditions applicable to JACKSON’s MICE, PRODUCTS or services. In addition, special terms and conditions of sale of certain MICE, PRODUCTS or services may be set forth separately in JACKSON web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, PRODUCTS and services by JACKSON, and by its licensees and distributors.

Acceptance of delivery of MICE, PRODUCTS or services shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on JACKSON, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, PRODUCTS or services by JACKSON.


(6.8)